EyeGate Promotes Sarah Romano to Chief Financial Officer
January 04, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye
December 19, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment
December 18, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
November 14, 2017 08:00 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 14, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery
November 08, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy
November 01, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
Eye Care Thought Leaders Join EyeGate Scientific Advisory Board
October 23, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company focused on developing...
EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships
September 11, 2017 06:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing...
EyeGate Pharma to Present at the 19th Annual Rodman and Renshaw Global Investment Conference
September 05, 2017 06:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing...
EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
August 07, 2017 07:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...